The industry analysts at Thomson Reuters put their heads together to tap the biggest new blockbusters in the making this year and surprised no one by capping the list with Gilead's Sovaldi.
Teva Pharmaceutical Industries is one of half a dozen drugmakers that have been rolling out generics of Eli Lilly's top-selling blockbuster Cymbalta. The others are going to roll past the Israeli drugmaker after it recalled more than 1 million bottles of the antidepressant.
U.S. lawmakers have asked the U.S. Trade Representative's office to put Canada on a "priority watch list" because it has invalidated patents on drugs made by Eli Lilly and others.
One of the big surprises at the annual meeting of the American Association for Cancer Research last weekend belonged to none other than Eli Lilly, which will soon be able to add another therapy to its list of Phase III assets in the clinic.
A Louisiana jury pummeled Takeda Pharmaceutical and Eli Lilly & Co. with $9 billion in punitive damages in a liability suit over their blockbuster diabetes drug Actos. It's one for the record books, an amount so far beyond normal that even the victorious lawyers discounted it.
Track-and-trace is on its way. Eli Lilly, with its 10-year history of fighting counterfeits, is in a good position to make the switch, and now it's putting the wheels in motion to get the project underway.
Eli Lilly has been combatting counterfeiters for more than 10 years, but now, the drugmaker has decided it's time to up its efforts. It's latest move: Investing $110 million into stamping unique codes and serial numbers on every drug package it sells worldwide, making them trackable--and hopefully stumping crafty counterfeiters in the process.
The Lieber Institute for Brain Development is partnering with Astellas, Eli Lilly, Lundbeck, Pfizer and Roche to launch an early-stage research consortium to study the genetic mechanisms at work in brain disorders.
Moving pharma's IT into the cloud could save a lot of money, the IMS Institute for Healthcare Informatics told us a few weeks ago. Eli Lilly may not yet know that firsthand. But its reps do know that cloud-based systems save them a lot of aggravation.
Eli Lilly just scored billions in additional sales. A federal judge decreed that an unusual patent on Lilly's cancer drug Alimta is valid. And that means the company keeps its Alimta exclusivity till 2022.